Back to the directory

InVision Medical Technology

AI Diagnosis of Heart Disease

Founded
2022
Status
Active
Stage
Early
Team size
2
Location
San Francisco, CA, USA
Category
Biotech & Drug Discovery
Sector
Healthcare

About InVision Medical Technology

At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.

Artificial IntelligenceDiagnosticsHealth Tech

FDA clearances

2 510(k) clearances on record, 2024 to 2025.

  • InVision Precision Cardiac Amyloid
  • InVision Precision LVEF (LVEF)

K232331, K243866

Source: FDA 510(k) database via openFDA.

Company data compiled and maintained by Healthcare Discovery.